International Journal of Gynecology & Obstetrics
Volume 83, Issue 3 , Pages 285-291 , December 2003

Dysmenorrhea treatment with a single daily dose of rofecoxib

Received 17 February 2003 ,Revised 5 May 2003 ,Accepted 7 May 2003.

References 

  1. Jamieson DJ, Steege JF. The prevalence of dysmenorrhea, dyspareunia, pelvic pain, and irritable bowel syndrome in primary care practices. Obstet Gynecol. 1996;87:55–58
  2. Dawood MY. Dysmenorrhoea and prostaglandins: pharmacological and therapeutic considerations. Drugs. 1981;22:42–56
  3. Lundstrom V, Green K. Endogenous levels of prostaglandin F2alpha and its main metabolites in plasma and endometrium of normal and dysmenorrheic women. Am J Obstet Gynecol. 1978;130:640–646
  4. Chan WY, Dawood MY, Fuchs F. Relief of dysmenorrhea with the prostaglandin synthetase inhibitor ibuprofen: effect on prostaglandin levels in menstrual fluid. Am J Obstet Gynecol. 1979;135:102–108
  5. Nigam S, Benedetto C, Zonca M, Leo-Rossberg I, Lubbert H, Hammerstein J. Increased concentrations of eicosanoids and platelet activating factor in menstrual blood women with primary dysmenorrhea. Eicosanoids. 1991;4:137–141
  6. Bieglmayer C, Hofer G, Kainz C, Reinthaller A, Kopp B, Janisch H. Concentrations of various arachidonic acid metabolites in menstrual fluid are associated with menstrual pain and are influenced by hormonal contraceptives. Gynecol Endocrinol. 1995;9:307–312
  7. Dawood MY. Ibuprofen and dysmenorrhea. Am J Med. 1984;77:87–94
  8. Dawood MY. Nonsteroidal anti-inflammatory drugs and changing attitudes toward dysmenorrhea. Am J Med. 1988;84:23–29
  9. Koike H, Egawa H, Ohtsuka T, Yamaguchi M, Ikenoue T, Mori N. Correlation between dysmenorrheic severity and prostaglandin production in women with endometriosis. Prostaglandins Leukot Essent Fatty Acids. 1992;46:133–137
  10. Dawood MY. Nonsteroidal antiinflammatory drugs and reproduction. Am J Obstet Gynecol. 1993;169:1255–1265
  11. Kniss DA. Cyclooxygenases in reproductive medicine and biology. J Soc Gynecol Invest. 1999;6:285–292
  12. Kulkarni SK, Jain NK, Singh A. Cyclooxygenase isoenzymes and newer therapeutic potential for selective COX-2 inhibitors. Methods Find Exp Clin Pharmacol. 2000;22:291–298
  13. Golden BD, Abramson SB. Selective cyclooxygenase-2 inhibitors. Rheum Dis Clin North Am. 1999;25:359–378
  14. Scott LJ, Lamb HM. Rofecoxib. Drugs. 1999;58:499–507
  15. Matheson AJ, Figgitt DP. Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis. Drugs. 2001;61:833–865
  16. Morrison BW, Daniels SE, Kotey P, Cantu N, Seidenberg B. Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial. Obstet Gynecol. 1999;94:504–508
  17. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 1991;115:787–796
  18. Vane JR, Botting RM. Mechanism of action of anti-inflammatory drugs. Int J Tiss React. 1998;20:3–15
  19. Peura DA. Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors. Cleve Clin J Med. 2002;69:SI31–SI39
  20. Simon LS. COX-2 inhibitors. Are they nonsteroidal anti-inflammatory drugs with a better safety profile?. Gastroenterol Clin North Am. 2001;30:1011–1025
  21. Noble SL. Cyclooxygenase-2 enzyme inhibitors: place in therapy. Am Fam Physician. 2000;61:3669–3676
  22. Schafer AI. Effects of nonsteroidal anti-inflammatory therapy on platelets. Am J Med. 1999;106:25S–36S

PII: S0020-7292(03)00260-1

doi: 10.1016/S0020-7292(03)00260-1

International Journal of Gynecology & Obstetrics
Volume 83, Issue 3 , Pages 285-291 , December 2003

Article Tools

* Image Usage & Resolution